COVID-19 : Global Status / Stephen Berger and Gideon science GIDEON science team.

Format:

Book

Author/Creator:

Berger, Stephen, 1939- author.

GIDEON science team, Gideon science, author.

Contributor:

GIDEON science team, Gideon science, author.

Language:

English

Subjects (All):

COVID-19 (Disease).

Physical Description:

1 online resource (1175 pages)

Edition:

2024th ed.

Place of Publication:

Los Angeles, California : GIDEON Informatics, Inc, [2024]

Summary:

COVID-19: Global Status is one in a series of GIDEON ebooks which explore all individual infectious diseases, drugs, vaccines, outbreaks, surveys and pathogens in every country of the world. Data are based on the GIDEON web application ( www.gideononline.com ) which relies on standard text books, peer-review journals, Health Ministry reports and ProMED, supplemented by an ongoing exhaustive search of the medical literature. The ebook includes: 1. Descriptive epidemiology 2. Clinical features 3. Distribution map 4. Images 5. Global status and status in every relevant country 6. References

Contents:

Intro

Copyright

Introduction: The GIDEON e-book series

Table of Contents

COVID-19

Epidemiology

Agent

Reservoir

Vector

Vehicle

Incubation Period

Diagnostic Tests

Typical Adult Therapy

Typical Pediatric Therapy

Vaccines

Clinical Hints

Synonyms

References

Clinical

Distribution Map

Images

Global status

Afghanistan

Albania

Algeria

American Samoa

Andorra

Angola

Anguilla

Antigua and Barbuda

The Antilles (miscellaneous)

Argentina

Armenia

Aruba

Australia

Austria

Azerbaijan

The Azores

The Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bermuda

Bhutan

Bolivia

Bosnia and Herzegovina

Botswana

Brazil

The British Virgin Islands

Brunei

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

The Canary Islands

Cape Verde

The Cayman Islands

Central African Republic

Chad

Chile

China

Colombia

The Comoros and Mayotte

Congo

The Cook Islands

Costa Rica

Croatia

Cuba

Cyprus

References.

The Czech Republic

The Democratic Republic of Congo

Denmark

Djibouti

Dominica

The Dominican Republic

Ecuador

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Eswatini

Ethiopia

The Falkland Islands

Fiji

Finland

France

French Guiana

French Polynesia

Gabon

Gambia

Georgia

Germany

Ghana

Gibraltar

Greece

Greenland

Grenada

Guadeloupe

Guam

Guatemala

Guinea

Guinea Bissau

Guyana

Haiti

Honduras

Hong Kong

Hungary

Iceland

India

Indonesia

Iran

Iraq

Ireland

Israel

Italy

Ivory Coast

Jamaica

Japan

Jordan

Kazakhstan

Kenya

Kiribati

Kosovo

Kuwait

Kyrgyzstan

Laos

Latvia

Lebanon

Lesotho

Liberia

Libya

Liechtenstein

Lithuania

Luxembourg

Macao

Madagascar

Malawi

Malaysia

The Maldives

Mali.

References

Malta

The Marshall Islands

Martinique

Mauritania

Mauritius

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Montserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

The Netherlands

New Caledonia

New Zealand

Nicaragua

Niger

Nigeria

Niue

North Macedonia

Northern Ireland

The Northern Marianas

Norway

Oman

Pakistan

Palau

Panama

Papua New Guinea

Paraguay

North Korea

Peru

The Philippines

Pitcairn Island

Poland

Portugal

Puerto Rico

Qatar

South Korea

Reunion

Romania

The Russian Federation

Rwanda

Samoa

San Marino

Sao Tome and Principe

Saudi Arabia

Scotland

Senegal

Serbia

The Seychelles

Sierra Leone

Singapore

Slovakia

Slovenia

The Solomon Islands

Somalia

South Africa

South Sudan

Spain

Sri Lanka

St. Helena

Saint Kitts and Nevis

Saint Lucia

Saint Vincent and The Grenadines

Sudan

Suriname

Sweden

Switzerland

Syria

Taiwan

Tajikistan

Tanzania

Thailand

Timor-Leste

Togo

Tokelau

Tonga

Trinidad and Tobago

Tunisia

Turkey

Turkmenistan

The Turks and Caicos Islands

Tuvalu

Uganda

Ukraine

The United Arab Emirates

The United Kingdom

The United States

Uruguay

Uzbekistan

Vanuatu

Venezuela

Vietnam

The U.S. Virgin Islands

Wallis and Futuna Islands

Western Sahara

Yemen

Zambia

Zimbabwe

Vaccines &amp

Immunoglobulins

Bamlanivimab

Mechanism of Action

Typical Adult Dosage

Typical Pediatric Dosage

Subsequent booster

Toxic Effects for Bamlanivimab (2 listed)

Contraindications for Bamlanivimab (0 listed)

Trade names of Bamlanivimab (3 listed)

Bebtelovimab

Toxic Effects for Bebtelovimab (5 listed)

Contraindications for Bebtelovimab (0 listed)

Trade names of Bebtelovimab (1 listed)

Bimervax

Toxic Effects for Bimervax (6 listed)

Contraindications for Bimervax (2 listed)

Trade names of Bimervax (1 listed)

Casirivimab / Imdevimab

Mechanism of Action.

Typical Adult Dosage

Toxic Effects for Casirivimab / Imdevimab (6 listed)

Contraindications for Casirivimab / Imdevimab (1 listed)

Trade names of Casirivimab / Imdevimab (2 listed)

COVID-19 - inactivated vaccine

Toxic Effects for COVID-19 - inactivated vaccine (13 listed)

Contraindications for COVID-19 - inactivated vaccine (2 listed)

Trade names of COVID-19 - inactivated vaccine (14 listed)

COVID-19 - mRNA vaccine

Toxic Effects for COVID-19 - mRNA vaccine (16 listed)

Contraindications for COVID-19 - mRNA vaccine (1 listed)

Trade names of COVID-19 - mRNA vaccine (8 listed)

COVID-19 - recombinant nanoparticle vaccine

Toxic Effects for COVID-19 - recombinant nanoparticle vaccine (7 listed)

Contraindications for COVID-19 - recombinant nanoparticle vaccine (2 listed)

Trade names of COVID-19 - recombinant nanoparticle vaccine (10 listed)

COVID-19 - viral vector vaccine

Toxic Effects for COVID-19 - viral vector vaccine (11 listed)

Contraindications for COVID-19 - viral vector vaccine (1 listed)

Trade names of COVID-19 - viral vector vaccine (14 listed)

Pemivibart

Toxic Effects for Pemivibart (2 listed)

Contraindications for Pemivibart (1 listed)

Trade names of Pemivibart (1 listed)

Regdanvimab

Typical Adult Dosage.

Typical Pediatric Dosage.

Notes:

Description based on publisher supplied metadata and other sources.

Description based on print version record.

ISBN:

1-4988-4241-0

OCLC:

1439603015